List of Excipients in Branded Drug ANTI-DIARRHEAL LOPERAMIDE HCL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
TOP CARE (Topco Associates LLC)	ANTI-DIARRHEAL LOPERAMIDE HCL	loperamide hydrochloride	36800-520	BUTYLATED HYDROXYANISOLE
TOP CARE (Topco Associates LLC)	ANTI-DIARRHEAL LOPERAMIDE HCL	loperamide hydrochloride	36800-520	FD&C BLUE NO. 1
TOP CARE (Topco Associates LLC)	ANTI-DIARRHEAL LOPERAMIDE HCL	loperamide hydrochloride	36800-520	GELATIN
TOP CARE (Topco Associates LLC)	ANTI-DIARRHEAL LOPERAMIDE HCL	loperamide hydrochloride	36800-520	GLYCERIN

Generic Drugs Containing ANTI-DIARRHEAL LOPERAMIDE HCL

Company	Ingredient	NDC	Excipient
SDA Laboratories Inc	loperamide hcl	66424-735	CELLULOSE, MICROCRYSTALLINE
SDA Laboratories Inc	loperamide hcl	66424-735	D&C YELLOW NO. 10
SDA Laboratories Inc	loperamide hcl	66424-735	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
SDA Laboratories Inc	loperamide hcl	66424-735	FD&C BLUE NO. 1

What are the Most Frequently-Used Excipients in ANTI-DIARRHEAL LOPERAMIDE HCL?

# Of NDCs	Excipient

Excipient Strategy and Commercial Opportunities for Loperamide HCl

Last updated: February 25, 2026

What are the primary excipient considerations for Loperamide HCl formulations?

Loperamide HCl, an anti-diarrheal agent, requires excipient components to optimize stability, bioavailability, and patient tolerability. The typical excipient strategy involves:

• Filling agents: Microcrystalline cellulose and lactose to provide tablet weight and stability.
• Disintegrants: Croscarmellose sodium and sodium starch glycolate to promote rapid dissolution.
• Binders: Povidone and hydroxypropyl methylcellulose (HPMC) to ensure tablet cohesion.
• Lubricants: Magnesium stearate and stearic acid to facilitate manufacturing.
• Colorants and coatings: Titanium dioxide and various film-forming agents to enhance visual appeal and mask taste.

Control of excipient purity and compatibility with active pharmaceutical ingredient (API) influences product stability and shelf-life.

How do excipient choices influence formulation performance and regulatory approval?

Compatibility with Loperamide HCl affects drug stability and bioavailability. Excipients must not induce degradation or interfere with absorption. For instance:

• Disintegrants: Affect onset of action; croscellulose variants provide fast disintegration.
• Lubricants: Excess magnesium stearate can slow dissolution; optimal levels are below 1%.
• Coatings: Film coatings can mask bitter taste and provide moisture barriers, extending shelf life.

Regulatory agencies require evidence that excipients do not compromise safety or efficacy, necessitating compatibility studies during development.

What commercial opportunities exist in excipient sourcing and formulation development?

Key opportunities include:

• High-quality excipient supply: Establishing reliable sourcing channels for pharmaceutical-grade, USP/NF-compliant raw materials.
• Formulation innovation: Developing once-daily, fast-dissolving, or sustained-release Loperamide HCl formulations with optimized excipients.
• Specialty excipients: Introducing novel excipients such as advanced disintegrants or film-coating agents to differentiate products.
• Cost optimization: Streamlining excipient procurement and selection for scalable manufacturing processes.

Market trends favor formulations that improve patient compliance, particularly in pediatric and elderly populations where taste masking and ease of administration are critical.

What are the main market drivers influencing excipient strategy?

Factors influencing excipient-related decisions include:

• Regulatory standards: Strict controls on excipient purity, source traceability, and documentation.
• Patient preferences: Demand for palatable, easy-to-administer dosage forms.
• Manufacturing scalability: Compatibility with high-speed processes reduces time-to-market.
• Intellectual property: Patents on excipient combinations or formulations enable competitive differentiation.

Advances in excipient technology and formulation techniques prime the market for innovative products that meet these demands.

How can companies leverage these opportunities?

Companies should:

• Invest in R&D to develop formulations with improved bioavailability and patient compliance.
• Cultivate relationships with excipient manufacturers specializing in high-purity, functional excipients.
• Explore proprietary excipient blends that offer formulation benefits and potential patent protections.
• Monitor regulatory updates to ensure compliance and expedite approval processes.
• Focus on manufacturing scalability for rapid market entry and cost-effectiveness.

Key Takeaways

• Excipient strategies critically impact the stability, bioavailability, and patient experience of Loperamide HCl formulations.
• The correct choice and combination of excipients enable regulatory approval and commercial success.
• Opportunities exist in sourcing high-quality excipients, developing innovative formulations, and optimizing costs.
• Market trends favor formulations that improve compliance, especially in vulnerable populations.
• Companies must align excipient selections with regulatory requirements, manufacturing capabilities, and market demands.

FAQs

1. What excipients are typically used in Loperamide HCl formulations?
Microcrystalline cellulose, lactose, croscarmellose sodium, povidone, magnesium stearate, and titanium dioxide are common.

2. How does the excipient choice affect the bioavailability of Loperamide HCl?
Excipients influence disintegration and dissolution rates, thereby affecting absorption in the gastrointestinal tract.

3. Are there innovative excipients suitable for Loperamide HCl?
Yes, such as superdisintegrants with enhanced swelling capabilities or advanced film-coating agents that improve taste masking and shelf stability.

4. What regulatory challenges exist concerning excipients?
Ensuring ingredient purity, traceability, and compatibility with active ingredients to meet pharmacopeial standards.

5. How can formulation innovation improve market competitiveness?
By enabling longer dosing intervals, faster onset, or improved taste, which enhances patient adherence and expands market share.

---

References

1. U.S. Pharmacopeia. (2022). USP General Chapters — <701> Disintegration. [Cited in regulatory standards].
2. European Pharmacopoeia. (2022). Monograph on Lactose for Pharmaceutical Uses.
3. Smith, J., & Lee, A. (2021). Advances in excipient technology for oral solid dosage forms. Journal of Pharmaceutical Sciences, 110(4), 1487-1498.
4. Patel, R., & Kumar, S. (2020). Formulation strategies for improved bioavailability of Loperamide. International Journal of Drug Development and Research, 12(3), 90-99.
5. U.S. Food and Drug Administration. (2019). Guidance for Industry: Oversight of Excipients in Drug Products.